Neprilysin inhibition for pulmonary arterial hypertension: a randomized, double‐blind, placebo‐controlled, proof‐of‐concept trial

BACKGROUND AND PURPOSE: Pulmonary arterial hypertension (PAH) is an incurable, incapacitating disorder resulting from increased pulmonary vascular resistance, pulmonary arterial remodelling, and right ventricular failure. In preclinical models, the combination of a PDE5 inhibitor (PDE5i) with a nepr...

Full description

Saved in:
Bibliographic Details
Published in:Br J Pharmacol
Main Authors: Hobbs, Adrian J., Moyes, Amie J., Baliga, Reshma S., Ghedia, Dipa, Ochiel, Rachel, Sylvestre, Yvonne, Doré, Caroline J., Chowdhury, Kashfia, Maclagan, Kate, Quartly, Harriet L., Sofat, Reecha, Smit, Angelique, Schreiber, Benjamin E., Coghlan, Gerry J., MacAllister, Raymond J.
Format: Artigo
Language:Inglês
Published: John Wiley and Sons Inc. 2019
Subjects:
Research Papers
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651846/
https://ncbi.nlm.nih.gov/pubmed/30761523
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.14621
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items